Istaroxime stimulates SERCA2a and accelerates calcium cycling in heart failure by relieving phospholamban inhibition
British Journal of Pharmacology2013Vol. 169(8), pp. 1849–1861
Citations Over TimeTop 10% of 2013 papers
Mara Ferrandi, Paolo Barassi, Francesco Tadini‐Buoninsegni, Gianluca Bartolommei, Isabella Molinari, María Tripodi, Cristina Reina, Maria Rosa Moncelli, Giuseppe Bianchi, Paolo Ferrari
Abstract
Istaroxime represents the first example of a small molecule that exerts a luso-inotropic effect in the failing human heart through the stimulation of SERCA2a ATPase activity and the enhancement of Ca(2) (+) uptake into the SR by relieving the PLB inhibitory effect on SERCA2a in a cAMP/PKA independent way.
Related Papers
- → Phosphorylated Phospholamban Stabilizes a Compact Conformation of the Cardiac Calcium-ATPase(2013)50 cited
- → Phosphorylated Phospholamban Stabilizes a Distinct Compact Conformation of Sarco(endo)Plasmic Reticulum Ca-ATPase(2013)
- → Phospholamban Phosphorylation Alters its Conformational Equilibrium to Regulate SERCA Activity(2015)
- → Solid-State NMR Structures of Phospholamban or Sarcolipin Bound to Calcium ATPase (SERCA) Reveal the Mode of Inhibition(2014)
- → EPR Detects Changes in the Transmembrane Region of the SERCA-Phospholamban Complex upon Ser16 Phosphorylation(2013)